Protalix Biotherapeutics And Chiesi Global Rare Diseases Provide Regulatory Update On PRX-102 For The Treatment Of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary